Moderna, Inc. has announced that it will present five abstracts related to its investigational mRNA therapeutics at the upcoming 2025 International Congress of Inborn...
Moderna is poised to seek regulatory approval for its mRNA flu vaccine following a successful Phase III trial. The vaccine, known as mRNA-1010, demonstrated...